Hereditary breast and ovarian cancer BRCA1 and/or BRCA2 variant carriers ovarian, fallopian tube, and peritoneal carcinoma
Conditions
Interventions
None listed
Sponsors
Japanese Gynecologic Oncology Group(JGOG)
Korean Gynecologic Oncology Group
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Women carrying BRCA1/2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS). (2) Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study. (3) Women who provide consent should be 20 years of age or older. (4) Women who provide written consent.
Exclusion criteria
Exclusion criteria: (1) Women without ovarian or fallopian tube cancer at the time of informed consent. (2) Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development. (3)Other individuals considered inappropriate for involvement in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of ovarian, fallopian tube, and peritoneal carcinoma | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Development of ovarian, fallopian tube, and peritoneal cancers, and the detection rate of occult cancer, based on evaluations of histopathological samples taken post-RSSO. (2) Death from any cause (3) Deaths from ovarian, fallopian tube, and peritoneal cancers. (4) Establishing the detection rate of occult cancer based on histopathological evaluations of samples from RRSO. (5) Development of ovarian, fallopian tube, and peritoneal cancers, including in the post-RRSO period. (6)Death from any cause, including post-RRSO period. | — |
Countries
Japan,Asia(except Japan)
Contacts
Public ContactYuko Sano
Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovat Devision of project management
Outcome results
None listed